Compare · AMGN vs FRLN
AMGN vs FRLN
Side-by-side comparison of Amgen Inc. (AMGN) and Freeline Therapeutics Holdings plc (FRLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and FRLN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $239.09B, about 2048.4x FRLN ($116.7M).
- AMGN has hit the wire 18 times in the past 4 weeks while FRLN has been quiet.
- AMGN has more recent analyst coverage (25 ratings vs 6 for FRLN).
- Company
- Amgen Inc.
- Freeline Therapeutics Holdings plc
- Price
- -
- -
- Market cap
- $239.09B
- $116.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2020
- News (4w)
- 18
- 0
- Recent ratings
- 25
- 6
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Latest AMGN
- SVP, Business Development Khosla Rachna exercised 1,252 shares at a strike of $162.60 and sold $1,346,499 worth of shares (3,252 units at $414.05), decreasing direct ownership by 24% to 6,404 units (SEC Form 4) to satisfy tax liability
- VP, Finance & CAO Busch Matthew C. was granted 730 shares, increasing direct ownership by 17% to 5,080 units (SEC Form 4)
- Director Ishrak Omar was granted 85 shares, increasing direct ownership by 1% to 7,486 units (SEC Form 4)
- Director Holley Charles M was granted 103 shares, increasing direct ownership by 0.80% to 12,990 units (SEC Form 4)
- Director Drake Michael V was granted 64 shares, increasing direct ownership by 1% to 5,876 units (SEC Form 4)
- SVP, Human Resources Miller Derek exercised 3,890 shares at a strike of $169.56 and sold $1,565,898 worth of shares (3,890 units at $402.54) (SEC Form 4) (tax liability)
- SVP & CCO Grygiel Nancy A. exercised 2,970 shares at a strike of $177.41 and sold $1,194,415 worth of shares (2,970 units at $402.16) (SEC Form 4) (for withholding tax)
- Truist reiterated coverage on Amgen with a new price target
- Oppenheimer reiterated coverage on Amgen with a new price target
- Morgan Stanley reiterated coverage on Amgen with a new price target
Latest FRLN
- Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
- SEC Form 15-12G filed by Freeline Therapeutics Holdings plc
- SEC Form EFFECT filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form POS AM filed by Freeline Therapeutics Holdings plc
- SEC Form SC 13D/A filed by Freeline Therapeutics Holdings plc (Amendment)
- SEC Form SC 13E3/A filed by Freeline Therapeutics Holdings plc (Amendment)